GlassScriptPhysician profile
Jennifer E Cammarata
NPI 1144277385
$5,101.30
in general payments reported to CMS, 2019-2025
36 companies · $2,841 in 2025
The $2,841 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.96 · 2022: $1,149 · 2023: $634 · 2024: $458 · 2025: $2,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.28 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $862.44 | 2023-2025 | Carvykti, Rybrevant, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $449.34 | 2022-2025 | Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $270.16 | 2022-2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $263.69 | 2022-2025 | Wainua |
| Incyte Corporation | $249.98 | 2023-2025 | Jakafi, Jakafi |
| Alexion Pharmaceuticals, INC. | $243.66 | 2023 | Ultomiris |
| Neurelis, INC. | $213.03 | 2025 | Valtoco |
| Pfizer INC. | $199.10 | 2025 | |
| Abbvie INC. | $168.77 | 2021-2025 | |
| Axsome Therapeutics, INC. | $165.87 | 2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $145.40 | 2025 | Jemperli, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Stemline Therapeutics INC. | $124.98 | 2024 | Orserdu |
| Genmab U.S., INC. | $124.26 | 2025 | Tivdak |
| Exelixis INC. | $122.01 | 2025 | Cabometyx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $121.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2025 | Libtayo |
| Astellas Pharma US INC | $121.83 | 2025 | Vyloy |
| Seagen INC. | $121.83 | 2022 | |
| Boston Scientific Corporation | $107.38 | 2022 | |
| Genentech USA, INC. | $97.34 | 2022 | |
| Scynexis, INC. | $96.35 | 2022 | |
| Novo Nordisk INC | $86.19 | 2022 | |
| Emd Serono, INC. | $78.49 | 2025 | |
| Pharmacosmos Therapeutics INC. | $72.05 | 2025 | Monoferric |
| Ucb, INC. | $71.74 | 2025 | Rystiggo, Fintepla |
| Vanda Pharmaceuticals INC. | $60.45 | 2025 | Ponvory |
| Jazz Pharmaceuticals INC. | $51.65 | 2025 | |
| Csl Behring | $38.80 | 2025 | Hizentra |
| Lundbeck LLC | $25.05 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $19.38 | 2025 | Austedo Xr |
| Mallinckrodt Hospital Products INC. | $19.08 | 2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $17.26 | 2025 | |
| Tonix Medicines, INC. | $16.36 | 2025 | Zembrace Symtouch |
| Lilly USA, LLC | $14.39 | 2025 | Kisunla |
| Merz Pharmaceuticals, LLC | $14.31 | 2025 | Xeomin, Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cammarata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.